Literature DB >> 6965350

Selective binding of the factor VIII/von Willebrand factor protein to human platelets.

D K Morisato, H R Gralnick.   

Abstract

The factor VIII/von Willebrand factor protein was radiolabeled after modification by galactose oxidase and reduction with tritiated potassium borohydride. This mild efficient method for labeling resulted in retention of over 90% of the biologic activities of the factor VIII/von Willebrand factor protein. Binding of this protein to platelets was found to be specific, and binding sites could be saturated in the presence of ristocetin. However, binding was highly dependent on ristocetin concentration, as the number of human factor VIII/von Willebrand factor molecules bound per platelet was a function of the ristocetin concentration. At a ristocetin concentration of 0.55 mg/ml, each platelet binds approximately 11,000 factor VIII/von Willebrand factor molecules per platelet. Scatchard analysis of the concentration-dependent binding sites yielded a hyperbolic plot that appeared to be related to the existence of two classes of binding sites. The higher affinity class had a Kd of 3.7 x 10(-10) M 3500 sites/platelet, while the lower affinity class had a Kd of 2.35 x 10(-9) M and a capacity of 7500 sites/platelet. As with ristocetin-induced platelet agglutination, the carbohydrate content plays a significant role in the binding of the factor VIII/von Willebrand factor protein to the platelet.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6965350

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Circulating von Willebrand factor in inflammatory bowel disease.

Authors:  T R Stevens; J P James; N J Simmonds; D A McCarthy; I F Laurenson; P J Maddison; D S Rampton
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

2.  Identification and isolation of a platelet GPIb-like protein in human umbilical vein endothelial cells and bovine aortic smooth muscle cells.

Authors:  A S Asch; B Adelman; M Fujimoto; R L Nachman
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

3.  Thrombin-induced exposure and prostacyclin inhibition of the receptor for factor VIII/von Willebrand factor on human platelets.

Authors:  T Fujimoto; S Ohara; J Hawiger
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

4.  Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent.

Authors:  L De Marco; S S Shapiro
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

5.  Structural basis of von Willebrand factor binding to platelet glycoprotein Ib and collagen. Effects of disulfide reduction and limited proteolysis of polymeric von Willebrand factor.

Authors:  P Bockenstedt; J M Greenberg; R I Handin
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

6.  Platelet adhesive dynamics. Part II: high shear-induced transient aggregation via GPIbalpha-vWF-GPIbalpha bridging.

Authors:  Nipa A Mody; Michael R King
Journal:  Biophys J       Date:  2008-05-30       Impact factor: 4.033

7.  Glycogen storage disease type Ib: familial bleeding tendency.

Authors:  K Heyne; D Hosenfeld; W Grote; J Schaub
Journal:  Eur J Pediatr       Date:  1984-11       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.